Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?

Morten Ladekarl

doi:10.21037/cco-23-17

Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?

Morten Ladekarl^*

^*Kontaktforfatter

Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › peer review

1 Citationer (Scopus)

22 Downloads (Pure)

Originalsprog	Engelsk
Artikelnummer	10
Tidsskrift	Chinese clinical oncology
Vol/bind	12
Udgave nummer	2
Sider (fra-til)	10
Antal sider	1
ISSN	2304-3865
DOI	https://doi.org/10.21037/cco-23-17
Status	Udgivet - apr. 2023

Adgang til dokumentet

10.21037/cco-23-17Licens: CC BY-NC-ND 4.0

Ladekarl (2023). Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefitForlagets udgivne version, 136 KBLicens: CC BY-NC-ND 4.0

AUB Link

Søg efter materialet i Aalborg Universitetsbiblioteks søgemaskine

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{49cf857278284e7c9c3a8008421c0a1a,

title = "Pembrolizumab for second line treatment of advanced hepatocellular carcinoma-who would benefit?",

keywords = "Antibodies, Monoclonal, Humanized/pharmacology, Carcinoma, Hepatocellular/drug therapy, Humans, Liver Neoplasms/drug therapy, Sorafenib, pembrolizumab, second line, hepatocellular carcinoma (HCC), Immune check point inhibitor, randomized study",

author = "Morten Ladekarl",

year = "2023",

month = apr,

doi = "10.21037/cco-23-17",

language = "English",

volume = "12",

pages = "10",

journal = "Chinese clinical oncology",

issn = "2304-3865",